Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook

Positioned to increase depth of Vafseo prescribing entering 2026 with access to approximately 275,000 patients First patient dosed in ...

Harmony Biosciences Guides to Over $1 Billion in WAKIX(R) Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation

PLYMOUTH MEETING, Pa.-- (BUSINESS WIRE)--January 12, 2026-- ...
The Malaysian Reserve

Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Heal…

Reports positive early clinical experience from first and only clinically validated, extracellular protein degraders using ...
PharmiWeb

Harmony Biosciences Guides to Over $1 Billion in WAKIX® Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation

WAKIX 2025 Preliminary Net Revenue of ~$868 Million; 2026 WAKIX Net Revenue Guidance of $1.0 – $1.04 Billion on Track for Blockbuster Status in NarcolepsyOn Track to Extend the Pitolisant Franchise ...
Le Lézard

Lantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RADR® Platform and Accelerate Global Development Opportunities with BioPharma ...

Lantern Pharma Inc. , a pioneer in AI-driven precision oncology and computational therapeutic development, today announced the establishment of an A.I. Center of Excellence and Advanced Agentic Labs ...

WELT Unveils the World’s First “AI-Combo Drug” at CES 2026

Turning Any Medication into a Precision AI-Combo Drug through Simple QR-Code Integration LAS VEGAS, NV / ACCESS ...